PLARIUM
Plarium, a developer of mobile, social, and web-based games with more than 250 million users worldwide, is proud to announce the launch of RAID: Shadow Legends . Available now on the App Store and Google Play , the turn-based collection RPG invites players to fight and conquer a dark fantasy world with over 300 collectible champions across 16 factions. The game features entirely unique individual character models, deep tactics, unparalleled skill customization, and clan-driven cooperative play.
RAID is set in the realm of Teleria, tainted by a shadow cast by the Dark Lord Siroth. Players assume the role of an ancient Telerian warrior resurrected by an immortal guardian to defeat Siroth and restore peace to the realm. Along their journey, players will accumulate Shards, vessels containing the souls of past warriors, to assemble an army and battle across castles, deserts, dungeons and ancient temples guarded by foes and potential allies. Progression allows players to unravel the many layers behind the threat assailing Teleria.
RAID features an extensive story-driven single player (PvE) campaign with 12 campaign levels, each including seven stages and three difficulty levels. The narrative is written by Writers’ Guild of America-nominated Paul C.R. Monk from Assassin’s Creed: Syndicate , and features a fully-voiced cast that includes veterans from Mass Effect and The Witcher 3 . The campaign is interconnected with the multiplayer (PvP) component to determine the ranking system, offering one of the most unified game experiences in the collection RPG genre. Each of the 300+ collectible characters features unique motion-capture animations produced exclusively in Plarium’s in-house studio to create distinctive character traits and personas.
“RAID is the ultimate combination of fantasy RPG and battle collection on mobile, giving players an unprecedented depth of play, endless customization of a highly diverse cast of Champions, and thousands of hours of gameplay. They’ll battle tons of challenging bosses and other players on their quest, in a world with seemingly endless content,” says Nick Day, Creative Director at Plarium. “With player choice at the core of RAID’s experience, we took every liberty to establish a unique setting in which to explore, experiment, and win.”
Key gameplay features of RAID: Shadow Legends include:
- Over 300 collectible characters: Collect hundreds of good, evil, or neutral warriors from 16 factions. Assemble the best teams of Barbarians, Skinwalkers, Undead, Knights, Elves, and more to defeat enemies and recruit them to your army.
- 1+ Million Champion Builds: Enjoy unparalleled RPG skill customization and explore thousands of combinations of skills, artifacts, and mastery paths to give each Champion millions of possible builds.
- Massive PvE Campaign Map: Experience epic dark fantasy through 12 spectacular locations spread over a sprawling, fully-voiced story campaign. Special time-specific dungeons reward players with rare items and artifacts to power their Champions.
- PVP Arena & Rankings: Go head-to-head with other players to unlock special gear and climb the rankings in intense arena battles. The higher the ranking, the increased chance of rare gear and item drops.
- Deep Strategic Gameplay: Succeed by combining skill and knowledge. Train the right teams of Champions for the right challenges, and teach them devastating special skills, AOE attacks, and healing powers. Then unleash them in arena battles, dungeon runs, clan boss fights, and story missions.
- A Complete Clan Experience: RAID alongside your friends as you climb the Clan Rankings, earn Clan Activity bonuses, and cooperate on dungeon runs against epic bosses.
RAID: Shadow Legends is now available for users around the globe in Chinese (Simplified & Traditional), English, French, German, Italian, Japanese, Korean, Portuguese (Brazilian), Russian, Spanish, Ukrainian and Turkish.
About Plarium
Founded in 2009, Plarium Global Ltd. is dedicated to creating the best mobile and social experience for hardcore and casual gamers worldwide. With over 250 million registered users, we're proud to be consistently ranked among Facebook’s top hardcore game developers. Plarium employs more than 1200 individuals and is headquartered in Israel with eight offices and development studios across Europe and the United States. Our mobile and social games are available on all major social networks, including Facebook, VKontakte, Odnoklassniki and Mail.ru, as well as web browsers, iOS and Android. Plarium was acquired by Aristocrat in October 2017 and operates as a wholly owned subsidiary.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190228005070/en/
Contact:
Media Contacts: Deanna Dweck Plarium Phone: +972 9 9540211 ext. 116 Email: deanna@plarium.com Ross Blume Fusion PR for Plarium Phone: +1-310-481-1431 ext. 18 Email: ross.blume@fusionpr.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom